Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
9.0
6.0
Journals
Cells
Special Issues
Cell-Based Therapies for Cancers: Advances and Perspectives
share announcement

Cell-Based Therapies for Cancers: Advances and Perspectives

A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Cell and Gene Therapy".

Deadline for manuscript submissions: closed (15 May 2023) | Viewed by 5129

Special Issue Editor

Dr. Nagarajan Kannan

E-Mail Website
Guest Editor
Laboratory of Stem Cell and Cancer Biology, Mayo Clinic Cancer Center, Rochester, MN 55905, USA
Interests: epithelial stem cells; cancer; mammary gland; fallopian tube; salivary gland

Special Issue Information

Dear Colleagues,

Globally, nearly 10 million deaths a year are related to cancer. Curative treatments are not guaranteed for patients with metastatic cancers. There is a growing number of engineered cellular immunotherapies (T, NK, dendritic cell, macrophage) under development and they could provide further options for patients. Moreover, rapid advancements in the development of tissues from embryonic and adult stem cells has created newer opportunities to effectively address normal tissue toxicity associated with radio-chemotherapy for cancer patients. Together, these cellular therapeutics will play a major role in individualized cancer management strategies in the clinic.

This Special Issue will highlight emerging stem cell- and immune cell-based therapies for individualized cancer management.

Dr. Nagarajan Kannan
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cell-based immunotherapy
  • CAR-T therapy
  • dendritic cell therapy
  • engineered NK cell
  • engineered macrophage
  • tumor vaccine
  • iPSC-derived cell therapies for cancer
  • cellular therapy for cancer survivors

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

19 pages, 8258 KiB  
Article
Development of a Novel CD26-Targeted Chimeric Antigen Receptor T-Cell Therapy for CD26-Expressing T-Cell Malignancies
by Eiji Kobayashi, Yusuke Kamihara, Miho Arai, Akinori Wada, Shohei Kikuchi, Ryo Hatano, Noriaki Iwao, Takeshi Susukida, Tatsuhiko Ozawa, Yuichi Adachi, Hiroyuki Kishi, Nam H. Dang, Taketo Yamada, Yoshihiro Hayakawa, Chikao Morimoto and Tsutomu Sato
Cells 2023, 12(16), 2059; https://doi.org/10.3390/cells12162059 - 14 Aug 2023
Cited by 1 | Viewed by 1791
Abstract
Chimeric-antigen-receptor (CAR) T-cell therapy for CD19-expressing B-cell malignancies is already widely adopted in clinical practice. On the other hand, the development of CAR-T-cell therapy for T-cell malignancies is in its nascent stage. One of the potential targets is CD26, to which we have [...] Read more.
Chimeric-antigen-receptor (CAR) T-cell therapy for CD19-expressing B-cell malignancies is already widely adopted in clinical practice. On the other hand, the development of CAR-T-cell therapy for T-cell malignancies is in its nascent stage. One of the potential targets is CD26, to which we have developed and evaluated the efficacy and safety of the humanized monoclonal antibody YS110. We generated second (CD28) and third (CD28/4-1BB) generation CD26-targeted CAR-T-cells (CD26-2G/3G) using YS110 as the single-chain variable fragment. When co-cultured with CD26-overexpressing target cells, CD26-2G/3G strongly expressed the activation marker CD69 and secreted IFNgamma. In vitro studies targeting the T-cell leukemia cell line HSB2 showed that CD26-2G/3G exhibited significant anti-leukemia effects with the secretion of granzymeB, TNFα, and IL-8, with 3G being superior to 2G. CD26-2G/3G was also highly effective against T-cell lymphoma cells derived from patients. In an in vivo mouse model in which a T-cell lymphoma cell line, KARPAS299, was transplanted subcutaneously, CD26-3G inhibited tumor growth, whereas 2G had no effect. Furthermore, in a systemic dissemination model in which HSB2 was administered intravenously, CD26-3G inhibited tumor growth more potently than 2G, resulting in greater survival benefit. The third-generation CD26-targeted CAR-T-cell therapy may be a promising treatment modality for T-cell malignancies. Full article
(This article belongs to the Special Issue Cell-Based Therapies for Cancers: Advances and Perspectives)
►▼ Show Figures

Figure 1

Review

Jump to: Research

17 pages, 631 KiB  
Review
CAR T-Cell Therapy for Cancer: Latest Updates and Challenges, with a Focus on B-Lymphoid Malignancies and Selected Solid Tumours
by Hiu Kwan Carolyn Tang, Bo Wang, Hui Xian Tan, Muhammad Adeel Sarwar, Bahaaeldin Baraka, Tahir Shafiq and Ankit R. Rao
Cells 2023, 12(12), 1586; https://doi.org/10.3390/cells12121586 - 8 Jun 2023
Cited by 6 | Viewed by 2966
Abstract
Although exponential progress in treating advanced malignancy has been made in the modern era with immune checkpoint blockade, survival outcomes remain suboptimal. Cellular immunotherapy, such as chimeric antigen receptor T cells, has the potential to improve this. CAR T cells combine the antigen [...] Read more.
Although exponential progress in treating advanced malignancy has been made in the modern era with immune checkpoint blockade, survival outcomes remain suboptimal. Cellular immunotherapy, such as chimeric antigen receptor T cells, has the potential to improve this. CAR T cells combine the antigen specificity of a monoclonal antibody with the cytotoxic ‘power’ of T-lymphocytes through expression of a transgene encoding the scFv domain, CD3 activation molecule, and co-stimulatory domains. Although, very rarely, fatal cytokine-release syndrome may occur, CAR T-cell therapy gives patients with refractory CD19-positive B-lymphoid malignancies an important further therapeutic option. However, low-level expression of epithelial tumour-associated-antigens on non-malignant cells makes the application of CAR T-cell technology to common solid cancers challenging, as does the potentially limited ability of CAR T cells to traffic outside the blood/lymphoid microenvironment into metastatic lesions. Despite this, in advanced neuroblastoma refractory to standard therapy, 60% long-term overall survival and an objective response in 63% was achieved with anti GD2-specific CAR T cells. Full article
(This article belongs to the Special Issue Cell-Based Therapies for Cancers: Advances and Perspectives)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop